Liraglutide

"Liraglutide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

An analog of GLUCAGON-LIKE PEPTIDE 1 and agonist of the GLUCAGON-LIKE PEPTIDE 1 RECEPTOR that is used as a HYPOGLYCEMIC AGENT and supplemental therapy in the treatment of DIABETES MELLITUS by patients who do not respond to METFORMIN.

Descriptor ID	D000069450
MeSH Number(s)	D06.472.317.469.500.500.500
Concept/Terms	Liraglutide Liraglutide Victoza Victoza Saxenda Saxenda NN 2211 NN 2211 2211, NN NN2211 NN-2211

Below are MeSH descriptors whose meaning is more general than "Liraglutide".

Chemicals and Drugs [D]
Hormones, Hormone Substitutes, and Hormone Antagonists [D06]
Hormones [D06.472]
Gastrointestinal Hormones [D06.472.317]
Proglucagon [D06.472.317.469]
Glucagon-Like Peptides [D06.472.317.469.500]
Glucagon-Like Peptide 1 [D06.472.317.469.500.500]
Liraglutide [D06.472.317.469.500.500.500]

Below are MeSH descriptors whose meaning is related to "Liraglutide".

Below are MeSH descriptors whose meaning is more specific than "Liraglutide".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Liraglutide" by people in this website by year, and whether "Liraglutide" was a major or minor topic of these publications.

Bar chart showing 16 publications over 9 distinct years, with a maximum of 3 publications in 2016

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2014	0	2	2
2015	1	0	1
2016	3	0	3
2017	2	0	2
2018	1	1	2
2019	2	0	2
2020	1	1	2
2021	0	1	1
2022	1	0	1

Below are the most recent publications written about "Liraglutide" by people in Profiles.

Rubino DM, Greenway FL, Khalid U, O'Neil PM, Rosenstock J, Sørrig R, Wadden TA, Wizert A, Garvey WT. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022 01 11; 327(2):138-150.

View in: PubMed
Weeda ER, Muraoka AK, Brock MD, Cannon JM. Medication adherence to injectable glucagon-like peptide-1 (GLP-1) receptor agonists dosed once weekly vs once daily in patients with type 2 diabetes: A meta-analysis. Int J Clin Pract. 2021 Sep; 75(9):e14060.

View in: PubMed
Sivitz WI, Phillips LS, Wexler DJ, Fortmann SP, Camp AW, Tiktin M, Perez M, Craig J, Hollander PA, Cherrington A, Aroda VR, Tan MH, Krakoff J, Rasouli N, Butera NM, Younes N. Optimization of Metformin in the GRADE Cohort: Effect on Glycemia and Body Weight. Diabetes Care. 2020 05; 43(5):940-947.

View in: PubMed
Garvey WT, Birkenfeld AL, Dicker D, Mingrone G, Pedersen SD, Satylganova A, Skovgaard D, Sugimoto D, Jensen C, Mosenzon O. Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial. Diabetes Care. 2020 05; 43(5):1085-1093.

View in: PubMed
Wexler DJ, Krause-Steinrauf H, Crandall JP, Florez HJ, Hox SH, Kuhn A, Sood A, Underkofler C, Aroda VR. Baseline Characteristics of Randomized Participants in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care. 2019 11; 42(11):2098-2107.

View in: PubMed
Cianflone D, Rizvi AA, Rizzo M. Microvascular and macrovascular effects of liraglutide. Int J Cardiol. 2019 07 01; 286:17-18.

View in: PubMed
O'Neil PM, Birkenfeld AL, McGowan B, Mosenzon O, Pedersen SD, Wharton S, Carson CG, Jepsen CH, Kabisch M, Wilding JPH. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018 08 25; 392(10148):637-649.

View in: PubMed
Rizzo M, Nikolic D, Patti AM, Mannina C, Montalto G, McAdams BS, Rizvi AA, Cosentino F. GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms. Biochim Biophys Acta Mol Basis Dis. 2018 09; 1864(9 Pt B):2814-2821.

View in: PubMed
O'Neil PM, Aroda VR, Astrup A, Kushner R, Lau DCW, Wadden TA, Brett J, Cancino AP, Wilding JPH. Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials. Diabetes Obes Metab. 2017 11; 19(11):1529-1536.

View in: PubMed
Talmon GA, Wren JD, Nguyen CL, Pour PM. Pancreatic Polypeptide Cell Proliferation in the Pancreas and Duodenum Coexisting in a Patient With Pancreatic Adenocarcinoma Treated With a GLP-1 Analog. Pancreas. 2017 07; 46(6):820-824.

View in: PubMed

People

Explore

Similar Concepts

Top Journals